# Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

> **NCT00088491** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1205 (actual)

## Conditions studied

- Schizophrenic Disorders

## Interventions

- **DRUG:** Intramuscular Olanzapine Depot
- **DRUG:** Oral Olanzapine

## Key facts

- **NCT ID:** NCT00088491
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 1205 (ACTUAL)
- **Last updated:** 2007-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088491, "Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00088491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*